| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | AIM; DNMT; MCMT; CXXC9; HSN1E; ADCADN |
| Entrez GeneID | 1786 |
| clone | 1D5G2 |
| WB Predicted band size | 183.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human DNMT1 (AA: 1317-1616) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于DNMT1抗体的3篇参考文献及其简要摘要：
1. **"DNA methyltransferases: facts, clues, and mysteries"**
- **作者**: Bestor, T.H.
- **摘要**: 该文献系统总结了DNMT1的功能及其在DNA甲基化维持中的作用，描述了针对DNMT1抗体的开发和应用，验证了其在哺乳动物细胞中检测甲基化酶活性的特异性。
2. **"DNA methylation and gene silencing in cancer"**
- **作者**: Robertson, K.D., et al.
- **摘要**: 研究利用DNMT1特异性抗体分析肿瘤组织中DNMT1蛋白的表达水平，发现其在多种癌症中异常高表达，并与抑癌基因甲基化沉默相关。
3. **"Epigenetics in cancer: targeting chromatin modifications"**
- **作者**: Jones, P.A., Laird, P.W.
- **摘要**: 综述中讨论了DNMT1抗体在表观遗传学研究中的关键作用，包括染色质免疫沉淀(ChIP)和免疫印迹(Western blot)技术中的应用，以解析甲基化与癌症发展的关联。
4. **"Regulation of DNMT1 stability through SET7-mediated lysine methylation"**
- **作者**: Esteve, P.O., et al.
- **摘要**: 研究通过特异性抗体检测DNMT1的翻译后修饰，揭示了SET7介导的赖氨酸甲基化调控DNMT1蛋白稳定性及细胞周期依赖性的分子机制。
这些文献涵盖了DNMT1抗体的开发、验证及在表观遗传学、癌症研究中的关键应用场景。
DNA methyltransferase 1 (DNMT1) antibodies are essential tools for studying the role of DNMT1. a key enzyme responsible for maintaining DNA methylation patterns during replication. DNMT1 ensures the propagation of methylation marks to daughter strands, a critical process for epigenetic regulation, genomic stability, and gene silencing. Antibodies targeting DNMT1 enable researchers to detect its expression, localization, and interactions in various biological contexts, including cancer, development, and aging.
These antibodies are widely used in techniques like Western blotting, immunofluorescence, immunohistochemistry, and chromatin immunoprecipitation (ChIP). Specificity is crucial, as DNMT1 shares structural homology with other DNMT family members (e.g., DNMT3A/B). High-quality DNMT1 antibodies are typically validated using knockout cell lines or siRNA-mediated knockdown to confirm target selectivity.
In disease research, DNMT1 dysregulation is linked to malignancies, neurodegenerative disorders, and autoimmune diseases. Antibodies help identify overexpression or aberrant activity in tumors, assess therapeutic responses to DNMT inhibitors, or study epigenetic changes in neurological models. Some antibodies target specific domains (e.g., the N-terminal regulatory region or C-terminal catalytic domain), enabling functional studies of DNMT1’s role in chromatin binding or enzyme processivity.
Commercial DNMT1 antibodies are available as monoclonal or polyclonal variants, each offering trade-offs between specificity and signal intensity. Proper controls and validation remain critical to avoid cross-reactivity with paralogs or post-translationally modified DNMT1 isoforms.
×
